SCHEMBL4723244

SCHEMBL4723244

CCCOc1ccc2c(c1-c1ccccc1)[CH]c1ccccc1-2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 3/20 0.38
TP53 P04637 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
ADRB2 P07550 3/20 0.38
HTR7 P34969 1/20 0.36
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
PTPN11 Q06124 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765920 0.93 CYP1A2 (0.42) KDM4EALDH1A1GAAADRB2HTR7
SCHEMBL4722390 0.89 ALDH1A1 (0.38) KDM4EMAPTALDH1A1MEN1USP2
SCHEMBL4723334 0.82 CNR1 (0.43) MEN1GAAKMT2ACYP2C9L3MBTL1
SCHEMBL4723230 0.81 ALDH1A1 (0.43) KDM4EMAPTALDH1A1TP53MEN1
SCHEMBL4916059 0.79 CYP1A2 (0.42) KDM4EMAPTALDH1A1TP53MEN1
SCHEMBL4723465 0.76 GAA (0.45) TP53GAACYP1A2CYP2C9CYP2C19
SCHEMBL217922 0.75 ELANE (0.34) KDM4EMAPTALDH1A1GAAHTT
SCHEMBL217599 0.75 L3MBTL1 (0.32) KDM4EMAPTALDH1A1TP53HTT
SCHEMBL1539778 0.73 ALDH1A1 (0.40) MAPTALDH1A1HTTHTR7MAPK1
SCHEMBL217878 0.72 ALDH1A1 (0.36) MAPTALDH1A1HTTKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 KDM4E 2584/4885MAPT 4361/4885ALDH1A1 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.